Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by bilosellhion May 22, 2003 1:36pm
308 Views
Post# 6109143

RE: Brad on burn rate

RE: Brad on burn rateHe said that they expect the burn rate to be stabilizing over the next two years at about C$600,000 per month, which is a little higher than they have been over the last quarter. i'm sure they will want to cause the exercise of warrants to raise another $1.5M and to that end do what they can to get the stock well above the $3 exercise price. that would give them a little breathing room (but not much) to operate for another quarter, and perhaps give them additional time to possibly issue further interim results and hopefully have those help drive the price higher to then do a financing. the $6.8M cash at March 31, 2003, less $1.2M for April & May, leaves them with $5.6 at the end of this month (or about 9 months of cash left.) i think they need to get the warrants exercised soon. the longer they defer a financing, the more they expose the company to market manipulation, especially if they experience more delays in trials, issuance of results, etc.
Bullboard Posts